Amgen and Servier said they reached an agreement to potentially market each other’s heart drugs and co-develop another experimental drug.
Amgen will pay $50 million plus future milestone and royalty payments for the US sales rights to Servier’s ivabradine for...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
